The ATP-dependent uptake of L-glutamate into synaptic vesicles has been well characterized, implicating a key role for synaptic vesicles in glutarnatergic neurotransmission. In the present study, we provide evidence that vesicular glutamate uptake is selectively inhibited by the peptide-containing halogenated ergot bromocriptine. It is the most potent inhibitor of the agents tested; the ICso was determined to be 22 pM. The uptake was also inhibited by other ergopeptines such as ergotamine and ergocristine, but with less potency. Ergots devoid of the peptide moiety, however, such as ergonovine, Iergotrile, and methysergide, had little or no effect. Although bromocriptine is known to elicit doparninergic and serotonergic effects, its inhibitory effect o n vesicular glutamate uptake was not mimicked by agents known to interact with dopamine and serotonin receptors. Kinetic data suggest that bromocriptine competes with glutarnate for the glutamate binding site on the glutamate translocator. It is proposed that this inhibitor could be useful as a prototype probe in identifying and characterizing the vesicular glutamate translocator, as well as in developing a more specific inhibitor of the transport system.
It is now widely accepted that glutamate functions as a major excitatory neurotransmitter in the vertebrate CNS (for reviews see Watkins and Evans, 1981; Cotman et al., 198 1 ; Fonnum, 1984; Ueda, 1986; Cotman et al., 1987; Nicholls, 1989) and at the neuromuscular junction of arthropods (Usherwood, 198 1) . The neurotransmitter glutamate is released from nerve terminals on their depolarization in a calcium-dependent manner (Bradford et al., 1973; Reubi and Cuknod, 1979; Cotman et al., 198 1 ; Levi et al., 1982) . Nicholls and Sihra (1986) have provided evidence that a noncytosolic pool of glutamate is rapidly released in a Ca2+-dependent manner, suggesting a role for synaptic vesicles in glutamate synaptic transmission. Glutamate has been shown to be specifically taken up into highly purified, isolated synaptic vesicles in an ATP-dependent manner Ueda, 1983, 1985; Maycox et al., 1988) , in accord with the immunocytochemical evidence that glutamate is concentrated in synaptic vesicles in certain nerve endings that are distinct from y-aminobutyric acid (GABA)-rich nerve terminals (Storm-Mathisen et al., 1983) . The vesicular glutamate uptake is driven by an electrochemical proton gradient, which is generated by a proton pump Mg-ATPase, and stimulated by physiologically relevant concentrations ofchloride (Naito and Ueda, 1985; Maycox et al., 1988; Shioi et al., 1989) . The high degree of specificity and the unique properties of the vesicular glutamate uptake system have led to the proposal that whether or not glutamate is utilized as a neurotransmitter is determined by the presence or absence of the glutamatespecific vesicular translocator (Ueda, 1986) . Recent studies by Fischer-Bovenkerk et al. (1988) suggest that the vesicular glutamate system is present in cerebellar granule cells, which are considered to be glutamatergic, but not in GABAergic Purkinje cells. Moreover, such a vesicular uptake system has been shown to develop in close parallel with the time course of synaptogenesis ( a s h et al., 1989~) . These lines of evidence all point to the importance of the vesicular glutamate uptake system in glutamate synaptic transmission. In this study, we have begun to investigate pharmacological
means by which the vesicular glutamate transport system can be modulated. We provide evidence suggesting that the peptide-containing halogenated ergot bromocriptine may serve as a prototype agent for developing a more specific, potent regulator of the vesicular glutamate transport system.
MATERIALS AND METHODS

Materials
L-Glutamic acid (potassium salt), ATP, bromocriptine, aergocriptine, ergonovine, and ergotamine tartrate were purchased from Sigma. Ergocristine methanesulfonate and dihydroergocriptine (Sandoz Pharmaceuticals) were generously provided by Dr. Edward Domino, Department of Pharmacology, the University of Michigan. Huphenazine was a gift from E. R. Squibb and Sons, Princeton. NJ 
Preparation of synaptic vesicles
Rat crude synaptic vesicles (RCSV) were prepared as described by Kish and Ueda (1989) . In brief, rat cerebrum was homogenized in solution A (0.32 M sucrose, 0.5 mM calcium acetate, 1 mM magnesium acetate, and 1 mM NaHC03) and centrifuged at 12,100 g,,, for 20 min (10,000 rpm, Sorvall SS-34 rotor). The pellet was lysed for 45 rnin in 6 mM Trismaleate (pH 8.1) and centrifuged at 43,500 g,,, for 15 rnin (1 9,000 rpm, Sorvall SS-34 rotor). The supernatant was centrifuged at 200,000 g,,, for 50 rnin (47,000 rpm, Beckman TI 50 rotor) to pellet the synaptic vesicles. This crude vesicle preparation, which was resuspended in solution €3 (0.32 M sucrose, 1 mM dithiothreitol, 1 mM NaHC03), was used in most of the experiments to be described here, except where otherwise indicated. Although there was some ATP-independent glutamate uptake activity in the RCSV preparation, it represented only about 10% of the ATP-dependent uptake activity.
Assay for vesicular glutamate uptake
Vesicular glutamate uptake was assayed essentially as described previously by Ueda (1983, 1985) . The standard incubation mixture for the glutamate uptake contained, in a final volume of 100 pl, 50 fig of RCSV, 5 mM Tris-maleate (pH 7.4), 4 mM MgS04, 0.25 M sucrose, 2 mM L-aspartate, 0 or 2 mM ATP neutralized with Tris-base, 4 mM KCI, and 50 pM potassium ~-['H]glutamate (0.4 Ci/ mmol). Aspartate was included to block any glutamate uptake into resealed plasma membrane vesicles, and to block any binding to glutamate receptors occurring from any plasma membrane contamination in the crude synaptic vesicle preparation used in these experiments. Synaptic vesicles (10 pl containing approximately 50 pug of protein) and the Tris/ sucrose medium (70 pl) were preincubated at 30°C for 5 rnin and then mixed with 20 pl of a prewarmed glutamate/ATP mixture including the KCI and [3H]glutamate. The mixture was incubated for an additional 1.5 min. The glutamate uptake was terminated by the addition of 2.0 ml of ice-cold 0.15 M KCI, followed by immediate filtration through Millipore H A W filters (25 mm, 0.45 pm). The incubation tubes were washed with the KCl solution three times, and the filters were then washed four more times. Radioactivity retained on the filters (dpm) was determined in ACS (Amersham) by using a liquid scintillation spectrophotometer (Beckman LS 9000). The amounts of radioactive glutamate nonspecifically bound to the filters were determined as follows: the prewarmed [3H]glutamate/ATP mixture was mixed with 2.0 ml of KCI solution and filtered; the filters were then washed with the KCI solution five more times. The radioactivity retained on the filters (400-900 dpm) was subtracted from all of the values presented in the uptake experiments described here. The means 2 SEM of triplicate determinations were presented. All glutamate uptake values presented represent ATPdependent uptake activity, which was defined as the activity observed in the presence of ATP minus the activity observed in its absence, unless otherwise indicated. Synaptic vesicle protein was determined according to Lowry et al. (195 1) with bovine serum albumin used as standard.
RESULTS
Effects of ergots on vesicular glutamate uptake
Figure 1 A and B shows the results of an experiment in which a number of derivatives of ergot alkaloids were tested for their effects on the ATP-dependent uptake of glutamate into RCSV. Bromocriptine, an ergot with dopamimetic properties (Fuxe et al., 1978 ; Kebabian a n d Calne, 1979), in micromolar concentrations, caused a marked inhibition of ATP-dependent glutamate uptake into RCSV. Bromocriptine was the most potent inhibitor of glutamate uptake of the various ergot derivatives tested, with an ICS0 of 22 + 6 pM. ICS0 values (the concentration of inhibitor that inhibited 50% of the ATP-dependent glutamate uptake activity) were obtained by log-logit transformation of the data in Fig. 1A and B. In other experiments not shown here, however, the potent dopamine agonist apomorphine (100 p M ) did not inhibit glutamate uptake. Moreover, inhibition of glutamate uptake was not observed with a n y of the dopamine antagonists tested (at concentrations up to 500 pUn4): trifluoperazine, fluphenazine, chlorpromazine, and sulpiride (data not shown). In addition, this inhibitory effect on glutamate uptake by bromocriptine was not mimicked by any of the serotonergic agonists or antagonists tested (at 500 p M ) : lysergic acid diethylamide, bromolysergic acid diethylamide, and methysergide (not shown).
These observations suggest that the inhibitory effect of bromocriptine is not mediated through dopamine or serotonin receptor mechanisms.
Bromocriptine is structurally classified as a peptide alkaloid or ergopeptine, containing a peptide moiety attached t o the ergoline ring structure (Rall and Schleifer, 1980) . To determine whether the inhibitory effect of bromocriptine is attributable to the ergoline ring structure, the peptide moiety, or to both, the various ergot compounds were tested for their ability to inhibit the ATP-dependent glutamate uptake. As shown in [3H]Glutamate uptake activity is expressed as percent of the activity in the absence of test agent (control). The glutamate uptake in the control was 11.5 +-0.24 pmol/l.5 min. All of the ergots except ergonovine and lergotrile were dissolved in 50% or 75% (for a-ergocriptine only) ethanol to make a stock solution of 10 mM. Ethanol alone at a concentration of 0.5% (the concentration used for M ergot), or less, had no effect on glutamate uptake. Ethanol at 2.5%, the concentration used for 500 pM ergot, lowered the glutamate uptake 42%. This control value was used to determine the effect of this concentration of waterinsoluble ergot. The data on bromocriptine and the other ergots are representative of five and three individual experiments, respectively.
GL UT,4MA T E UPTAKE INHIBITION BY BROMOCRIPTINE
The various ergots inhibited the ATP-independent uptake 5-1 0% only at the two highest concentrations of ergot tested (100 and 500 pM).
= 57 k 10 p M ) , dihydroergocriptine (IC50 = 73 & 3 p M ) , and ergocristine (IC5,, = 83 * 9 p M ) , were all effective but less potent than bromocriptine in inhibiting glutamate uptake. In contrast, those ergots that lack peptide moieties, such as lergotrile (ICsO > 500 p M ) and ergonovine (I& > 1 mM), had little or no effect. The presence of the bromine moiety also appears absence of ATP might represent glutamate binding to nonvesicular membrane proteins and/or to enzymes involved in the metabolism of glutamate. In an effort to determine whether bromocriptine interacts with the glutamate translocator component, kinetic experiments were carried out in the absence and presence of 10 and 20 uM bromocriptine. As shown in Fig. 3 , the V,,, of to enhance-the potency of the inhibitory kffect on glutical to bromocriptine except that it lacks the bromine moiety, has a reduced potency. Therefore, it appears that both the peptide and bromine moieties attached tamate uptake, because a-ergocriptine, which is iden- to the ergoline ring structure are important in causing a potent and selective inhibition of ATP-dependent glutamate uptake.
5:
Nature of the bromocriptine inhibition Figure 2 shows a time course of glutamate uptake 10 Bromocriptine showed its inhibitory effect throughout the incubation times tested; however, the effect decreased in magnitude with increasing incubation time. A preincubation time of 30 s is sufficient to achieve a maximal inhibitory effect by a given concentration of bromocriptine (data not shown), suggesting that full TIME (min) interaction between bromocriptine and a component of the glutamate uptake system occurs within 30 s. glutamate uptake was determined to be 0.26 k 0.02 nmol/min in both the absence and presence of 10 or 20 pM bromocriptine. Corresponding K, values were 2.05 k 0.04, 4.41 * 0.06, and 6.10 f 0.09 mM, respectively. Thus, the inhibitory action of bromocriptine is reflected in a change (increase) in the K, for glutamate, and not in changes in the V,,, of the uptake system. These results suggest that the nature of the inhibitory effect on glutamate uptake by bromocriptine is competitive with respect to glutamate. Other experiments not presented in this study failed to support the possibility that bromocriptine inhibits glutamate uptake by inhibiting the Mg-ATPase hydrolysis activity in the synaptic vesicle. Bromocriptine ( 1 -100 p M ) exhibited no effect on the Mg-ATPase activity. Moreover, the degree of the bromocriptine inhibition was not affected by varying the concentration of ATP from 0.05 to 2 mM. These studies lend further support to the notion that the glutamate translocator is the site of action of bromocriptine.
I S
Effect of bromocriptine on ATP-dependent vesicular uptake of GABA and glycine
The amino acids GABA and glycine are also taken up into synaptic vesicles in an ATP-dependent manner (Kish et al., 1987 Fykse and Fonnum, 1988; ., 1988). These uptake systems are distinct from each other and from the glutamate uptake system ( a s h et al., 19896) . In an effort to substantiate the selective action of bromocriptine on the glutamate translocator, we have examined the effect of the ergot on the ATP-dependent vesicular uptake of GABA and glycine in comparison with the effect on vesicular glutamate uptake. As shown in Table 1 , the inhibitory effect of bromocriptine is greater on the glutamate uptake system than on the GABA and glycine uptake systems. There was some inhibition by bromocriptine of the ATP-independent uptake activity; the inhibition of glutamate uptake in the cerebral synaptic vesicles and spinal cord vesicles was 2 and 8%, respectively, and the inhibition for both GABA and glycine uptake was 8%. These results suggest that the inhibitory action of bromocriptine is selective for the ATP-dependent glutamate uptake system.
DISCUSSION
In this study, we have demonstrated that bromocriptine selectively inhibits the ATP-dependent glutamate uptake into synaptic vesicles. The kinetic data shown in Fig. 3 indicate that the nature of bromocriptine's inhibitory action on uptake is competitive, with respect to glutamate, in that the V,,, of glutamate uptake is unchanged, whereas the K, for glutamate is increased. These results suggest that bromocriptine is acting at the glutamate translocator site of the synaptic vesicle, thereby preventing the uptake of glutamate into synaptic vesicles.
Bromocriptine's competitive interaction at the glutamate translocator site is substantiated further by studies that demonstrated that increasing the concentration of glutamate attenuated bromocriptine's ability to inhibit the vesicular glutamate uptake (data not presented). The competitive inhibition of glutamate uptake by bromocriptine also appears to be reversible, because removal of bromocriptine by centrifugation followed by incubation and subsequent centrifugation of the synaptic vesicles in the presence of high concentrations of glutamate (e.g., 50 mM) reversed the inhibitory effect of bromocriptine (not shown). This supports the view that the bromocriptine interaction with the glutamate translocator is via noncovalent bonding.
Other experiments not presented in this study suggested that bromocriptine does not inhibit the MgATPase hydrolysis activity in the synaptic vesicle. In addition, using the fluorescent probes Oxonol VI and Acridine Orange, which are indicators of membrane potential (Russell, 1984) and pH gradients (Xie et al., 19831 , respectively, we observed that bromocriptine had no detectable effect on the membrane potential or pH gradient across the synaptic vesicle membrane (results not shown).
Although bromocnptine is known to mimic some of the dopaminergic and serotonergic effects, this study indicates that the inhibitory effect on vesicular glutamate uptake is not attributable to its dopaminergic and serotonergic properties. The data in Fig. 1 demonstrate that the tripeptide moiety of bromocriptine is crucial in achieving potent inhibition of glutamate uptake. Thus, ergonovine, which is devoid of the peptide moiety, exhibited no effect even at 1 mM, the highest In the experiments in the upper half, crude synaptic vesicles were prepared from rat cerebrum as described by ffish and Ueda (1 989) and purified further by discontinuous sucrose-density gradient (0.4,0.6, and 0.8 Msucrose) centrifugation at 141,400 g,, for 120 min (28,000 rpm, SW 28 rotor), and 100 pg of vesicle protein were used per assay. In those in the lower half, synaptic vesicles were purified from rat spinal cord by Percoll-density gradient centrifugation as described by Kish et al., (19896) , and 150 pg of vesicle protein were used per assay. Vesicular amino acid uptake was assayed as described previously by Kish et al. (19896) , using 150 F M ~-[~H]glutamate, [3H]GABA, or ['Hlglycine (each 0.13 Ci/ mmol), using 10 mM ATP in the absence or presence of 100 p M bromocriptine (in 0.5% ethanol) in the standard incubation medium described for glutamate uptake in Materials and Methods, except that 0.5% ethanol was included in the control and the assay volume was 200 pl. Uptake was allowed to occur for 5 min at 30°C. The data are representative of two separate experiments; the variation in the percent inhibition from this experiment was 5-14%.
concentration tested, whereas all the ergots containing the peptide moiety tested are capable of inhibiting the glutamate uptake at much lower concentrations. The bromine moiety appears to enhance the inhibitory potency.
Consistent with the notion that bromocriptine interacts with the vesicular glutamate translocator is evidence that the halogenated ergot selectively inhibited the glutamate uptake. Thus, GABA and glycine uptakes were less affected (Table 1) . In addition to its interaction with the vesicular glutamate uptake system, bromocriptine has been reported to inhibit the high-affinity glutamate reuptake system in striatal membranes (Nieoullon et al., 1982) . However, in contrast to its effect on the vesicular uptake system, the inhibition appeared to be achieved through activation of D2-like dopamine receptors located on the presynaptic corticostriatal glutamatergic nerve endings. The authors proposed that nigrostriatal dopaminergic input may regulate corticostriatal glutamatergic activity. We have also observed the inhibitory effect of bromocriptine on the sodium-dependent glutamate uptake into synaptosomes; in our experiments, 20 pLM bromocriptine inhibited about 30% of the glutamate uptake into synaptosomes in the presence of 50 pA4 glutamate. The glutamate reuptake system located on synaptosomal plasma membranes has quite different characteristics from the vesicular glutamate uptake system, particularly with respect to its ability to recognize asparate (Logan and Snyder, 1972; Naito and Ueda, 1985) . The inhibitory effects on these two types of glutamate transport systems, one in the synaptic vesicle membrane and the other in the presynaptic plasma membrane, raises the possibility that in vivo short exposure to bromocriptine could prolong or potentiate the glutamate-evoked excitation by inhibiting the reuptake of glutamate from the synaptic cleft. Longer exposures could lead to hypoglutamatergic transmission by depleting vesicular glutamate pools. Because bromocriptine is a selective transport inhibitor with reasonable potency, it is also possible that it could serve as a prototype probe in identifying and characterizing the glutamate translocator in a purified synaptic vesicle preparation.
